trial

Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizophrenia.

NCTId NCT02876900
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 3 · Completed
Enrollment 617 (actual)
Sponsored by Noven Pharmaceuticals, Inc.
Primary completion 2018-06
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 3
Status
Completed
Enrollment
617 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
Triple
Start
2016-08
Primary completion
2018-06
Eligibility
ALL · 18 Years

Interventions & indications

Drugs
Asenapine

Sponsors

Noven Pharmaceuticals, Inc.Lead Sponsor

Investigators

1
George Harb, MD, MPHStudy Director

Sites

1 total
Jersey City, United States

Linked catalysts

1
Study to Assess Efficacy and Safety of HP3070 in Subjects Diagnosed With Schizop — primary completion2018-06

Facts & assertions

4 sourced
Enrollment
617
Phase
PHASE3
Primary Completion Date
2018-06
Status
COMPLETED
relationships
The graph out of here
drug
Asenapine
drug
lead_sponsor
Noven Pharmaceuticals, Inc.
company
indication
Schizophrenia
indication
Schizophrenia
indication
investigator
George Harb, MD, MPH
person